Clinical Trials List
Protocol NumberD9891C00001
Active
2025-10-01 - 2029-12-31
Phase I/II
Recruiting2
xxxxxx
-
Trial Applicant
-
Sponsor
xxxxxx
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 倪紹之 Division of Hematology & Oncology
- 莊佩儒 Division of Nuclear Medicine
- KUAN-YIN KO Division of Nuclear Medicine
- 劉家豪 Division of Hematology & Oncology
- 邱柏儒 Division of Hematology & Oncology
- 王昱弘 Division of Hematology & Oncology
- 魏兆宏 Division of Hematology & Oncology
- Chieh-Lung Cheng Division of Hematology & Oncology
- 陳睿哲 Division of Hematology & Oncology
- 洪聖祐 Division of Hematology & Oncology
- 劉高郎 Division of Radiology
- 林耘曲 Division of Hematology & Oncology
- MING YAO Division of Hematology & Oncology
- CHENG-HONG TSAI Division of Hematology & Oncology
- CHING-CHU LU Division of Nuclear Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Principal Investigator
PO-WEI LIAO
Co-Principal Investigator
- Chieh-Lin Teng Division of Hematology & Oncology
- Tsung -Chih Chen Division of Hematology & Oncology
- CHENG-HSIEN LIN Division of Hematology & Oncology
- FANG-LIANG HUANG Division of Pediatrics
- PO-HSIEN LI Division of Hematology & Oncology
- 鄧齡喬 Division of Hematology & Oncology
- 滕傑林 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
xxxxxx
Objectives
xxxxxx
Test Drug
xxxxxx
Active Ingredient
AZD4512
Dosage Form
243
Dosage
100 mg
Endpoints
xxxxxx
Inclution Criteria
xxxxxx
Exclusion Criteria
xxxxxx
The Estimated Number of Participants
-
Taiwan
12 participants
-
Global
120 participants
